Table 3. Prognostic factors for PFS for ICC patients after surgery.
| Factor | Univariate analysis | Multivariate analysisc | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age ≥60 years | 0.848 (0.579–1.240) | 0.395 | – | – | |
| Female | 0.841 (0.576–1.227) | 0.365 | – | – | |
| BMI ≥24 kg/m2 | 1.057 (0.722–1.548) | 0.775 | – | – | |
| Comorbidity | 0.819 (0.559–1.200) | 0.306 | – | – | |
| ASA score 3–4 | 1.347 (0.701–2.587) | 0.371 | – | – | |
| Preoperative therapy | 0.989 (0.666–1.469) | 0.956 | – | – | |
| Adjuvant therapy | 1.203 (0.585–2.473) | 0.616 | – | – | |
| Cirrhosis | 1.170 (0.794–1.725) | 0.427 | – | – | |
| HBsAg (+) | 1.188 (0.764–1.848) | 0.444 | – | – | |
| Microvascular invasion | 1.441 (0.851–2.439) | 0.174 | – | – | |
| T3–T4 stage | 1.717 (1.111–2.652) | 0.015 | – | – | |
| Complication | 1.004 (0.680–1.481) | 0.985 | – | – | |
| Lymph node metastasis | <0.001 | 0.006 | |||
| Undissected lymph node | Reference | Reference | |||
| Negative lymph node | 1.168 (0.725–1.883) | 0.523 | 1.521 (0.786–2.945) | 0.213 | |
| Positive lymph node | 2.821 (1.668–4.771) | <0.001 | 2.945 (1.426–6.084) | 0.004 | |
| Tumor size ≥5 cm | 1.308 (0.898–1.905) | 0.162 | – | – | |
| Multiple metastases | 1.757 (1.120–2.757) | 0.014 | 2.177 (1.266–3.744) | 0.005 | |
| Poorly differentiation | 1.409 (0.949–2.091) | 0.089 | 1.657 (1.039–2.643) | 0.034 | |
| Hemi-hepatectomy | 1.245 (0.850–1.824) | 0.260 | – | – | |
| Tumor location | – | – | |||
| Left liver lobe | Reference | – | |||
| Right liver lobe | 0.876 (0.645–1.188) | 0.394 | |||
| Other | 0.879 (0.653–1.184) | 0.397 | |||
| Operation time ≥230 mina | 1.420 (0.973–2.071) | 0.069 | – | – | |
| Blood loss ≥300 mL | 1.759 (1.186–2.608) | 0.005 | 1.842 (1.145–2.962) | 0.012 | |
| Tumor location | – | – | |||
| Central tumor | Reference | – | |||
| Edged tumor | 1.338 (0.920–1.946) | 0.127 | |||
| TBIL ≥21 μmol/L | 0.901 (0.483–1.682) | 0.744 | – | – | |
| AST ≥40 U/L | 1.571 (0.879–2.808) | 0.127 | – | – | |
| ALT ≥50U/L | 1.952 (1.085–3.510) | 0.026 | – | – | |
| GGT ≥60 U/L | 1.246 (0.850–1.825) | 0.260 | – | – | |
| Preoperative CA19-9 ≥871.65 U/mLa | 2.762 (1.696–4.496) | <0.001 | – | – | |
| Preoperative D-dimer ≥0.365 mg/La | 1.717 (1.176–2.507) | 0.005 | – | – | |
| Preoperative CEA ≥2.53 ng/mLa | 1.876 (1.271–2.770) | 0.002 | – | – | |
| Preoperative FIB ≥3.67 g/La | 2.069 (1.361–3.146) | 0.001 | – | – | |
| The prognostic value on CPDC scoreb | <0.001 | – | – | ||
| CPDC =0 | Reference | ||||
| CPDC =1 | 1.348 (0.843–2.154) | 0.213 | |||
| CPDC =2 | 3.117 (1.808–5.374) | <0.001 | |||
a, ROC curves were constructed to estimate the optimal cutoff value; b, because the CPDC score was based on the D-dimer levels and CA19-9 levels, the multivariate analysis of prognostic value of CPDC score included factors with a P<0.1 in univariate analysis exclude of the D-dimer levels and CA19-9 levels; c, clinicopathological factors with a P<0.1 in univariate analysis were included in multivariate analysis. Multivariable analysis was performed using Cox regression models. Forward: LR was used in multivariate analysis. PFS, progression-free survival; ICC, intrahepatic cholangiocarcinoma; OR, odds ratio; CI, confidence interval; BMI, body mass index; ASA, American Society of Anesthesiologists; HBsAg, serum hepatitis B surface antigen; TBIL, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; CEA, carcinoembryonic antigen; FIB, fibrinogen; CPDC, combination of preoperative D-dimer and CA19-9; BMI, body mass index; LR, likelihood ratio.